Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) received shareholder approval for the 2025 A Share Option Scheme at an extraordinary general meeting on 23 October 2025. Subsequently, on 4 November 2025, the board resolved to grant a total of 4,535,100 A Share Options, corresponding to approximately 0.1698% of the total number of shares in issue as of the same date. The exercise price for these options is set at RMB27.93 per share.

A total of 195 participants are included in this first grant, following the departure of six initially proposed participants who are no longer employed by the group. Certain participants under this grant are connected persons, constituting connected transactions under Chapter 14A of the Hong Kong Listing Rules. However, as all applicable percentage ratios for each such grant are below 0.1%, the transactions qualify for a full exemption from shareholders’ approval, annual review, and disclosure requirements.